Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma

Trial Profile

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Docetaxel (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Nanology
  • Most Recent Events

    • 06 Jun 2023 Results of 7 studies (NCT00666991, NCT03636256, NCT03077659, NCT04221828, NCT03029585, NCT03077685, NCT04314895) assessing safety findings in subjects co-administered LSAM-PTX or LSAM-DTX and common SOC therapies for treatment of carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Aug 2022 Results presented in a NanOlogy Media Release.
    • 16 May 2022 Results published in the Journal of Urology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top